Pro-2-PAM therapy for central and peripheral cholinesterases. 2010

James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
Walter Reed Army Institute of Research, Division of Regulated Activities, Department of Regulated Laboratories, Silver Spring, MD 20910-7500, United States.

Novel therapeutics to overcome the toxic effects of organophosphorus (OP) chemical agents are needed due to the documented use of OPs in warfare (e.g. 1980-1988 Iran/Iraq war) and terrorism (e.g. 1995 Tokyo subway attacks). Standard OP exposure therapy in the United States consists of atropine sulfate (to block muscarinic receptors), the acetylcholinesterase (AChE) reactivator (oxime) pralidoxime chloride (2-PAM), and a benzodiazepine anticonvulsant to ameliorate seizures. A major disadvantage is that quaternary nitrogen charged oximes, including 2-PAM, do not cross the blood brain barrier (BBB) to treat brain AChE. Therefore, we have synthesized and evaluated pro-2-PAM (a lipid permeable 2-PAM derivative) that can enter the brain and reactivate CNS AChE, preventing seizures in guinea pigs after exposure to OPs. The protective effects of the pro-2-PAM after OP exposure were shown using (a) surgically implanted radiotelemetry probes for electroencephalogram (EEG), (b) neurohistopathology of brain, (c) cholinesterase activities in the PNS and CNS, and (d) survivability. The PNS oxime 2-PAM was ineffective at reducing seizures/status epilepticus (SE) in diisopropylfluorophosphate (DFP)-exposed animals. In contrast, pro-2-PAM significantly suppressed and then eliminated seizure activity. In OP-exposed guinea pigs, there was a significant reduction in neurological damage with pro-2-PAM but not 2-PAM. Distinct regional areas of the brains showed significantly higher AChE activity 1.5h after OP exposure in pro-2-PAM treated animals compared to the 2-PAM treated ones. However, blood and diaphragm showed similar AChE activities in animals treated with either oxime, as both 2-PAM and pro-2-PAM are PNS active oximes. In conclusion, pro-2-PAM can cross the BBB, is rapidly metabolized inside the brain to 2-PAM, and protects against OP-induced SE through restoration of brain AChE activity. Pro-2-PAM represents the first non-invasive means of administering a CNS therapeutic for the deleterious effects of OP poisoning by reactivating CNS AChE.

UI MeSH Term Description Entries
D007531 Isoflurophate A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM. DFP,Diisopropylfluorophosphate,Fluostigmine,Bis(1-methylethyl) Phosphorofluoridate,Di-isopropylphosphorofluoridate,Diisopropylphosphofluoridate,Dyflos,Floropryl,Fluorostigmine,Di isopropylphosphorofluoridate
D008297 Male Males
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D011220 Pralidoxime Compounds Various salts of a quaternary ammonium oxime that reconstitute inactivated acetylcholinesterase, especially at the neuromuscular junction, and may cause neuromuscular blockade. They are used as antidotes to organophosphorus poisoning as chlorides, iodides, methanesulfonates (mesylates), or other salts. 2-PAM Compounds,Pyridine Aldoxime Methyl Compounds,2 PAM Compounds,Compounds, 2-PAM,Compounds, Pralidoxime
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002490 Central Nervous System The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges. Cerebrospinal Axis,Axi, Cerebrospinal,Axis, Cerebrospinal,Central Nervous Systems,Cerebrospinal Axi,Nervous System, Central,Nervous Systems, Central,Systems, Central Nervous
D002801 Cholinesterase Reactivators Drugs used to reverse the inactivation of cholinesterase caused by organophosphates or sulfonates. They are an important component of therapy in agricultural, industrial, and military poisonings by organophosphates and sulfonates. Insecticides, Organophosphate, Antagonists,Insecticides, Organothiophosphate, Antagonists,Organophosphate Insecticide Antagonists,Organothiophosphate Insecticide Antagonists,Antagonists, Organophosphate Insecticide,Antagonists, Organothiophosphate Insecticide,Insecticide Antagonists, Organophosphate,Insecticide Antagonists, Organothiophosphate,Reactivators, Cholinesterase
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms

Related Publications

James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
April 1978, Archives internationales de pharmacodynamie et de therapie,
James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
June 1962, The New physician,
James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
May 2017, ACS applied materials & interfaces,
James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
April 1958, Journal of the American Medical Association,
James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
November 1958, La Riforma medica,
James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
January 1946, Federation proceedings,
James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
January 1946, The American journal of physiology,
James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
April 2007, Regulatory toxicology and pharmacology : RTP,
James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
January 1955, Journal of neuropathology and experimental neurology,
James C Demar, and Edward D Clarkson, and Ruthie H Ratcliffe, and Amy J Campbell, and Sonia G Thangavelu, and Christine A Herdman, and Haim Leader, and Susan M Schulz, and Elizabeth Marek, and Marie A Medynets, and Therese C Ku, and Sarah A Evans, and Farhat A Khan, and Roberta R Owens, and Madhusoodana P Nambiar, and Richard K Gordon
January 1990, Pharmacological research,
Copied contents to your clipboard!